City of Hope adopts Quest's Haystack MRD test to improve cancer treatment monitoring.

City of Hope is implementing Quest Diagnostics' Haystack MRD test, a sensitive blood test detecting minimal residual disease in breast, colorectal, ovarian, and prostate cancers. This multi-year study across 14 U.S. sites aims to improve early detection of cancer recurrence and guide treatment decisions more effectively than traditional imaging. The test's ability to detect tumor DNA in blood could allow clinicians to act sooner, potentially sparing patients from unnecessary treatments. The collaboration highlights advances in liquid biopsy technology and its growing role in personalized cancer care.